News
Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 ...
8d
What Hi-Fi? on MSNFocal Bathys Mg
Focal has added new digital mics to the Bathys MG (the headphones use eight in total, four per earcup) in an attempt to ...
EXCLUSIVE: The Express's motoring expert Luke Chillingsworth got behind the wheel of the Jaecoo 7, the new Chinese SUV that ...
MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the second quarter ended June 30, 2025, and ...
JSW MG Motor India's top-selling electric car, the Windsor EV, has recorded its best-ever monthly sales, with 4,308 units retailed in July 2025. The car has surpassed the 36,000 unit sales milestone ...
TaylorMade’s forged MG5 wedges feature Spin Tread grooves for more spin in wet conditions and six grind options to suit every ...
Emergent BioSolutions Inc. (NYSE: EBS) today announces its recognition of the U.S. House of Representatives for adding over-the-counter (OTC) naloxone to every AED location in its buildings, providing ...
Net loss for the quarter ended June 30, 2025 was $84.7 million, compared to $57.9 million for the same period in 2024. The increase in net loss was primarily attributable to higher research and ...
8d
Press Trust of India on MSNIntas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA
Ahmedabad (Gujarat) [India], August 7: Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, has solidified its position as one of the world's leading ...
Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to ...
Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
The Company’s pre-clinical data demonstrates CRB-913 is markedly more peripherally restricted than either monlunabant or rimonabant. CRB-913 has a brain to plasma ratio 50-times lower than rimonabant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results